Dual Vaccine for Lassa Fever and Rabies Shows Early Promise in Clinical Trial

Initial human clinical trials for LASSARAB, a novel dual vaccine targeting Lassa fever and rabies, have yielded encouraging results. Researchers at the University of Maryland School of Medicine found the vaccine to be safe and effective in generating immune responses against both viruses. This development is significant, as there is currently no approved vaccine for Lassa fever.